NICE aims to cut funding for Amgen lung cancer drug Lumykras

Pharmaphorum

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

pharminent July 9, 2026 (Last updated: July 10, 2026)

Pharmaphorum

Amgen’s Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

Related Stories